| Primary information |
|---|
| sequence ID | Seq_7974 |
| Peptide sequence | SYKMADEAGSEADHEGTHST |
| CancerPDF_ID | CancerPDF_ID562, CancerPDF_ID1248, CancerPDF_ID1249, CancerPDF_ID2371, CancerPDF_ID8528, CancerPDF_ID9694, CancerPDF_ID9695, CancerPDF_ID12344, |
| PMID | 19795908,21136997,21136997,21136997,23667664,21533267,21533267,26992070 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Plasma,Serum,Serum,Plasma,Serum,Serum,Serum,Serum |
| M/Z | 1061.93,2121.85454,2137.84946,2121.8545,2121.85,708.28,713.6,NA |
| Charge | 2,1,1,1,1,3,3,NA |
| Mass (in Da) | NA,NA,NA,NA,2124.16,NA,NA,2122.858311 |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,NA,NA,NA,1.49,1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID562, CancerPDF_ID1248, CancerPDF_ID1249, CancerPDF_ID2371, CancerPDF_ID8528, CancerPDF_ID9694, CancerPDF_ID9695, CancerPDF_ID12344, |
| p-Value | NA,NA,NA,NA,NA,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,MASCOT,SEQUEST and Maxquant |
| Length | 20,20,20,20,20,20,20,20 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Lung adenocarcinoma,Melanoma |
| Database | NCBI refseq Protein Database,SwissProt Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4),Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,Oxidation of Met,NA,NA,NA,Oxidation,NA |
| Number of Patients | "42 normal, 28patients",30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | NA,NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." |
| Validation | NA,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates,na |
| Sensitivity | NA,NA,NA,NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |